Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-BCMA CAR-Tscm cells
- Development stage
- Unknown
- Lead developer
- Roche
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
Anti-BCMA CAR-Tscm cells are a chimeric antigen receptor (CAR) T-cell therapy specifically enriched for T memory stem cells (Tscm) and designed to target B-cell maturation antigen (BCMA). Tscm cells possess high self-renewal capacity, long-term persistence, and potent anti-tumor activity, making them an attractive vehicle for adoptive immunotherapy. By targeting BCMA, which is highly expressed on malignant plasma cells, these CAR-Tscm cells are developed as a potentially more durable and effective treatment for multiple myeloma compared to conventional CAR-T therapies.
- Other names
- anti-BCMA CAR-Tscm cell therapyBCMA CAR-Tscm cellsBCMA-targeted CAR-Tscm cells
02
Targets
TNFRSF9 (CD137 extracellular domain)BCMA (B-cell maturation antigen)CD3 (T-cell surface glycoprotein CD3)
Beyond the preview
Go deeper on anti-BCMA CAR-Tscm cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-BCMA CAR-Tscm cells.